Filtered By:
Condition: Atrial Fibrillation
Procedure: Percutaneous Coronary Intervention
This page shows you your search results in order of relevance. This is page number 7.
Order by Relevance | Date
Total 371 results found since Jan 2013.
One‐Year Outcome of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting: An Analysis of the AFCAS Registry
ConclusionsIn this large, real‐world population of AF patients undergoing PCI‐S, TT was the antithrombotic regimen most frequently prescribed. Although several limitations need to be acknowledged, in our study the 1‐year efficacy and safety of TT, dual antiplatelet therapy, and VKA plus clopidogrel was comparable.
Source: Clinical Cardiology - January 30, 2014 Category: Cardiology Authors: Andrea Rubboli, Axel Schlitt, Tuomas Kiviniemi, Fausto Biancari, Pasi P. Karjalainen, Josè Valencia, Mika Laine, Paulus Kirchhof, Matti Niemelä, Saila Vikman, Gregory Y. H. Lip, K. E. Juhani Airaksinen, Tags: Clinical Investigations Source Type: research
CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention
Conclusions: High CHA2DS2-VASc score was the best predictor of thrombotic outcomes after PCI in a high risk AF population. High mHAS-BLED score was not predictive of bleeding events. More accurate, simple risk scores are needed.
Source: Thrombosis Research - January 24, 2014 Category: Hematology Authors: Marja K. Puurunen, Tuomas Kiviniemi, Axel Schlitt, Andrea Rubboli, Britta Dietrich, Pasi Karjalainen, Kai Nyman, Matti Niemelä, Gregory Y.H. Lip, K.E. Juhani Airaksinen Tags: Clinical Studies Source Type: research
Performance of Bleeding Risk-Prediction Scores in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
In conclusion, the performance of ATRIA, HAS-BLED, mOBRI, and REACH scores in predicting bleeding complications in this high-risk patient subset was useless.
Source: The American Journal of Cardiology - April 3, 2014 Category: Cardiology Authors: Tuomas Kiviniemi, Marja Puurunen, Axel Schlitt, Andrea Rubboli, Pasi Karjalainen, Saila Vikman, Matti Niemelä, Heli Lahtela, Gregory Y.H. Lip, K.E. Juhani Airaksinen Tags: Coronary Artery Disease Source Type: research
Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
The prevalence, intensity, safety, and efficacy of oral anticoagulation (OAC) in addition to dual antiplatelet therapy (DAPT) in “real-world” patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) have not yet been fully evaluated. In the Coronary REvascularization Demonstrating Outcome Study in Kyoto registry cohort-2, a total of 1,057 patients with AF (8.3%) were identified among 12,716 patients undergoing first PCI. Cumulative 5-year incidence of stroke was higher in patients with AF than in no-AF patients (12.8% vs 5.8%, p
Source: The American Journal of Cardiology - April 25, 2014 Category: Cardiology Authors: Koji Goto, Kentaro Nakai, Satoshi Shizuta, Takeshi Morimoto, Hiroki Shiomi, Masahiro Natsuaki, Mitsuhiko Yahata, Chihiro Ota, Koh Ono, Takeru Makiyama, Yoshihisa Nakagawa, Yutaka Furukawa, Kazushige Kadota, Yoshiki Takatsu, Takashi Tamura, Akinori Takizaw Tags: Arrhythmias and Conduction Disturbances Source Type: research
Bare-Metal vs. Drug-Eluting Stents in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
Conclusions:In real-world patients with AF undergoing PCI, DES use was associated with outcomes comparable to those with BMS without excess bleeding complications. More ST was seen in BMS-treated patients.
PMID: 25298168 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 9, 2014 Category: Cardiology Authors: Kiviniemi T, Puurunen M, Schlitt A, Rubboli A, Karjalainen P, Nammas W, Kirchhof P, Biancari F, Lip GY, Airaksinen KJ Tags: Circ J Source Type: research
Particularities in coronary revascularization in elderly patients presenting with ST segment elevation acute myocardial infarction (STEMI)
Publication date: August 2014 Source:Cor et Vasa, Volume 56, Issue 4 Author(s): Maria Dorobanţu , Lucian Câlmâc , Andrada Bogdan , Vlad Bătăilă , Bogdan Drăgoescu , Andrei Radu , Mugur Marinescu , Şerban Arvanitopol , Gabriel Tatu-Chiţoiu , Rodica Niculescu Nowadays, ST elevation acute myocardial infarction (STEMI) is seen with greater incidence in older patients. Current guidelines recommend an immediate invasive evaluation and eventually primary percutaneous coronary intervention (PCI) in all STEMI patients regardless of age. Nevertheless, data in literature show a significant underuse of interventional treatm...
Source: Cor et Vasa - November 1, 2014 Category: Cardiology Source Type: research
Review of newer anticoagulants and anti-platelet agents in acute coronary syndrome and cardiovascular diseases.
Authors: Gosavi S, Mukherjee D
Abstract
In the last few years three new oral anticoagulants-Dabigatran, Rivaroxaban and Apixaban and two new antiplatelet agents Prasugrel and Ticagrelor have been approved for use. Dabigatran, Rivaroxaban and Apixaban have been approved for the prevention of stroke and systemic embolism in non valvular Atrial Fibrillation in the United States. Rivaroxaban is also approved for the prevention and treatment of venous thromboembolism, including pulmonary embolism. These drugs have been shown to be non-inferior to Warfarin. These drugs do not need monitoring and have lesser drug interact...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - November 23, 2014 Category: Cardiology Tags: Cardiovasc Hematol Agents Med Chem Source Type: research
Outcome of Early Revascularization Surgery in Patients with ST‐Elevation Myocardial Infarction
ConclusionsIn patients with ST‐elevation myocardial infarction who required emergency coronary artery bypass surgery, there was no difference in procedure complications or mortality between early (within 24 hours) or later (more than 24 hours). That was noted at one month and one year after the index myocardial infarction.
Source: Journal of Interventional Cardiology - December 1, 2014 Category: Cardiology Authors: Atif N. Khan, Salah Sabbagh, Sunitha Ittaman, Victor Abrich, Aarti Narayan, Bryan Austin, Shereif H. Rezkalla Tags: Original Investigation Source Type: research
Balancing the Risk of Bleeding and Stroke in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention (from the AVIATOR-registry)
We describe patterns and determinants of antithrombotic prescriptions in this population. The AVIATOR (Antithrombotic strategy Variability In ATrial fibrillation and Obstructive coronary disease Revascularized with PCI) Registry was an international observational study of 859 consecutive patients with AF undergoing PCI between 2009 and 2011.
Source: The American Journal of Cardiology - April 7, 2015 Category: Cardiology Authors: Marco G. Mennuni, Jonathan L. Halperin, Sameer Bansilal, Mikkel M. Schoos, Kleanthis N. Theodoropoulos, Omar A. Meelu, Samantha Sartori, Daniele Giacoppo, Chiara Bernelli, Pedro R. Moreno, Prakash Krishnan, Usman Baber, Carla Lucarelli, George D. Dangas, Source Type: research
Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey
The purpose of this European Heart Rhythm Association Survey was to assess the clinical practice in relation to the use of oral anticoagulation therapy for patients with atrial fibrillation (AF) in Europe. Of special interest were patients undergoing percutaneous coronary intervention (PCI), cardioversion procedures, catheter ablation, surgery, and those suffering from anticoagulation-related bleeding. Of 38 responding centres, non-vitamin K antagonist oral anticoagulants (NOACs) were used for stroke prophylaxis and were preferred (33.3%) or considered equal (48.5%) to vitamin K antagonists (VKAs). Only 3% did not use NOAC...
Source: Europace - April 29, 2015 Category: Cardiology Authors: Larsen, T. B., Potpara, T., Dagres, N., Proclemer, A., Sciarrafia, E., Blomstrom-Lundqvist, C., Scientific Initiative Committee, European Heart Rhythm Association, Scientific Initiative Committee, European Heart Rhythm Association, Blomstrom-Lundqvist, Bo Tags: EP WIRE Source Type: research
Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry)
We describe patterns and determinants of antithrombotic prescriptions in this population. The Antithrombotic Strategy Variability in Atrial Fibrillation and Obstructive Coronary Disease Revascularized with PCI Registry was an international observational study of 859 consecutive patients with AF who underwent PCI from 2009 to 2011.
Source: The American Journal of Cardiology - April 7, 2015 Category: Cardiology Authors: Marco G. Mennuni, Jonathan L. Halperin, Sameer Bansilal, Mikkel M. Schoos, Kleanthis N. Theodoropoulos, Omar A. Meelu, Samantha Sartori, Daniele Giacoppo, Chiara Bernelli, Pedro R. Moreno, Prakash Krishnan, Usman Baber, Carla Lucarelli, George D. Dangas, Tags: Coronary Artery Disease Source Type: research
0018 : Antithrombotic management in patients with atrial fibrillation undergoing stent implantation: An assessment of the ESC guidelines adherence
Conclusion Guidelines for antithrombotic therapy in patients with AF who undergo PCI and stent implantation are still poorly followed in clinical practice. OAC underused was associated with an increased risk of death in this population.
Source: Archives of Cardiovascular Diseases Supplements - May 8, 2015 Category: Cardiology Source Type: research
Predictive Accuracy Of CHADS-VASc and HAS-BLED Scores In Patients Without Atrial Fibrillation Undergoing Percutaneous Coronary Intervention And Discharged On Dual Antiplatelet Therapy
The CHA2DS2-VASc and HAS-BLED are well-validated stroke risk prediction scores for atrial fibrillation (AF), but their role in risk stratification of major adverse cardiac events (MACE) and major bleeding for non-AF patients undergoing percutaneous coronary intervention (PCI) is unknown.
Source: International Journal of Cardiology - July 25, 2015 Category: Cardiology Authors: Davide Capodanno, Roberta Rossini, Giuseppe Musumeci, Corrado Lettieri, Michele Senni, Orazio Valsecchi, Dominick J. Angiolillo, Gregory Y.H. Lip Source Type: research
Triple Therapy…Can We Replace More With Better? ∗
Triple therapy, or the use of oral anticoagulation (OAC) in addition to dual antiplatelet therapy (DAPT), is common among patients who have undergone percutaneous coronary intervention (PCI) and have concurrent indications for anticoagulation, such as atrial fibrillation (AF) or mechanical valve replacements. Patients are started on this therapy because of a concern for thrombotic events such as myocardial infarction, stent thrombosis, or embolic stroke. Unfortunately, this potent antithrombotic regimen also exposes patients to increased bleeding. While clinicians were quick to grasp the dangers of thrombotic events, only ...
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - August 3, 2015 Category: Radiology Source Type: research
Use of drug-eluting versus bare-metal stents after an acute coronary syndrome in Portugal: The EURHOBOP study
Conclusions Approximately two-thirds of patients received drug-eluting stents, which were less frequently implanted in patients with ST-elevation myocardial infarction, aged over 80 years, female, with a previous history of stroke, anticoagulation and/or atrial fibrillation and anemia. Patients who had previously undergone PCI and those with the anterior descending artery as the infarct-related artery were more likely to receive a drug-eluting stent.
Source: Revista Portuguesa de Cardiologia - August 5, 2015 Category: Cardiology Source Type: research
